Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180 is registered in ClinicalTrials.gov with Jacqueline Garcia, MD as lead sponsor.

NCT NCT07148180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07148180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Lead sponsor
Jacqueline Garcia, MD
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 2, 2026
Completion date
December 31, 2030
Enrollment
31 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukaemia (aml), blood cancer, blood cancers, leukemia